RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
  CAD
  CHF
  Clinical Trials
  Hypertension
   Pulmonary Hypertension
  Myocardial Infarction
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Hypertension Channel

subscribe to Hypertension newsletter
Latest Research : Cardiology : Hypertension

   EMAIL   |   PRINT
ASCOT Trial - Amlodipine Reduces Cardiovascular Mortality

Sep 8, 2005 - 1:05:00 AM , Reviewed by: Sanjukta Acharya
"The ASCOT results, including results of the Lipitor arm, play an essential role in effectively reducing cardiovascular events and death in hypertensive patients with additional risk factors," said Dr. Michael Berelowitz, Pfizer's senior vice president of Worldwide Medical and Outcomes Research.

 
[RxPG] Results of the landmark Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) showed that patients with high blood pressure and additional cardiovascular risk factors who received a treatment regimen based on Pfizer's calcium channel blocker Norvasc (amlodipine besylate) experienced significant reductions in cardiovascular death, all-cause mortality and total cardiovascular events and procedures, including heart attacks and strokes, compared to patients who received a standard beta-blocker based regimen.

Patients receiving the Norvasc-based regimen experienced a reduction in the primary endpoint (fatal coronary heart disease and non-fatal heart attack) which did not reach statistical significance. The final results of ASCOT confirmed the Data Safety and Monitoring Board decision to stop the trial early.

The results were presented this week at the annual meeting of the European Society of Cardiology in Stockholm, and September 4 online issue of The Lancet.

"The results of ASCOT clearly demonstrate that a Norvasc-based antihypertensive regimen can reduce the risk of cardiovascular death and a broad range of cardiovascular events in patients with hypertension who have additional risk factors," said Professor Peter Sever, ASCOT principle investigator, clinical pharmacology and therapeutics, International Centre for Circulatory Health at London's Imperial College.

The five-year ASCOT Study, which was one of the largest hypertension trials ever conducted, involved over 19,000 patients in Europe who had high blood pressure. The trial compared the cardiovascular effects of a Norvasc-based regimen versus a standard beta-blocker based regimen in reducing cardiac events in patients with hypertension and multiple cardiovascular risk factors. In the Norvasc-based regimen, patients received the ACE-inhibitor perindopril and the alpha-blocker Cardura XL (doxazosin GITS) as add-on therapy if additional blood pressure control was needed. Patients receiving the beta-blocker based regimen of atenolol, received a diuretic (thiazide) and Cardura XL (doxazosin GITS), if needed.

The final ASCOT results showed an 11 percent reduction in total mortality shown in patients taking the Norvasc-based regimen compared to patients taking the beta-blocker based regimen. Norvasc patients also experienced a 23 percent reduction in fatal and non-fatal strokes and a 24 percent reduction in cardiovascular death, compared to patients taking the beta-blocker-based regimen. In addition, patients taking the Norvasc based regimen experienced a 10 percent reduction in the primary endpoint of fatal coronary heart disease and non-fatal heart attack, which did not reach statistical significance.

"We have shown that an effective treatment strategy can provide the optimal benefits for patients and even save lives if physicians focus on early intervention that begins with targeting hypertension along with other cardiovascular risk factors such as lowering cholesterol with Lipitor," said Professor Sever.

In addition to treatment for high blood pressure, 10,000 patients in ASCOT who had normal to mildly elevated cholesterol levels—not typical candidates for lipid-lowering treatment—received Lipitor 10mg (atorvastatin calcium) or placebo to evaluate the cardiovascular benefits of lipid-lowering therapy. In October 2002, the lipid-lowering arm of ASCOT was stopped earlier than expected due to a significant benefit in the reduction of heart attacks in Lipitor-treated patients.

The results of the lipid lowering arm of ASCOT provided critical information in the development of national guidelines including the National Cholesterol Education Program and the Joint European Guidelines which now call for more aggressive lipid lowering in patients who have elevated cardiovascular risk, including patients with high blood pressure.

"The ASCOT results, including results of the Lipitor arm, play an essential role in effectively reducing cardiovascular events and death in hypertensive patients with additional risk factors," said Dr. Michael Berelowitz, Pfizer's senior vice president of Worldwide Medical and Outcomes Research. "These results imply that physicians may want to consider a more comprehensive approach to managing overall cardiovascular risk which may involve other available therapies such as Caduet, which offers the benefits of Norvasc and Lipitor in a single tablet."

Hypertension is one of the most prevalent risk factors for cardiovascular disease, affecting as many as 800 million people worldwide. It is estimated that at least 80 percent of people with high blood pressure may also have other uncontrolled cardiovascular risk factors with elevated cholesterol being the most common.

Funded by Pfizer, ASCOT was an investigator-led trial coordinated by an independent steering committee. The study began in 1998 and enrolled patients in the United Kingdom, Ireland, Sweden, Norway, Denmark, Finland and Iceland. In December 2004, the ASCOT steering committee endorsed the recommendation of the Data and Safety Monitoring Board to stop the trial early due to favorable benefits, including mortality, demonstrated in patients who received the Norvasc-based regimen.

Caduet is a prescription drug that combines 2 medicines, Norvasc® (amlodipine besylate) and Lipitor® (atorvastatin calcium). It is used to treat both high blood pressure (hypertension) or angina (chest pain) and high cholesterol, or to lower the risk of heart attack in patients with multiple risk factors for heart disease—such as family history of heart disease, high blood pressure, older than 55, low HDL-C, or smoking—along with diet and exercise.

Caduet is not for everyone. It is not for those with liver problems. And it is not for women who are nursing, are pregnant, or may get pregnant. Patients should tell their doctor if they feel any new muscle pain or weakness. This could be a sign of serious side effects. Patients should also tell their doctor about other medicines they are taking. This may help avoid serious drug interactions. The doctor may do blood tests to check liver function before and during treatment. If a patient has any heart problems, they should tell their doctor before taking Caduet. The most common side effects are edema, headache, and dizziness. They tend to be mild and often go away.

Norvasc (amlodipine besylate) is indicated for high blood pressure and angina. In clinical trials, the most common side effects for Norvasc versus placebo were edema (8.3% vs 2.4%), headache (7.3% vs 7.8%), fatigue (4.5% vs 2.8%), and dizziness (3.2% vs 3.4%).

The most common side effects are swelling, headache and dizziness. They tend to be mild and often go away. Patients should talk to their doctor about all medicines they are taking to help avoid serious drug interactions. Doctors may do blood tests to check liver function before and during treatment. Patients treated with Caduet should tell their doctor if they feel any new muscle pain or weakness which could be a sign of serious side effects.



Publication: Pfizer.com
On the web: Norvasc ® Full U.S. Prescribing Information 

Advertise in this space for $10 per month. Contact us today.


Related Hypertension News
Osmoreceptors in liver help increase blood pressure
Renal sympathetic nerve ablation may cure high blood pressure
Kids with hypertension more likely to fumble in studies
Need for a revamp of hypertension treatment
Scientists switch off nerves to treat high blood pressure
Low potassium levels likely to trigger high blood pressure
BP response to stress can point to better treatment
Statins may help lower blood pressure
Now a new way to regulate blood pressure
Posture linked to blood pressure

Subscribe to Hypertension Newsletter

Enter your email address:


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)